Synthetic Biologics - TOVX Net earnings per share for the last four quarters

The TTM YoY earnings per share metric on GURU.Markets demonstrates profitability trends, where the value 95.80 describes the current level. The biopharmaceutical sector remains stable, yet dependent on sanctions and patent disputes. Theriva Biologics, Inc. (TOVX) develops oncolytic viruses to combat tumor recurrences. Meanwhile, the company's environmental footprint is minimal due to the specific nature of laboratory testing.
TOVX (Theriva Biologics): analytical breakdowns and indicator data

Theriva Biologics, Inc. (TOVX) specializes in the development of oncology drugs and is currently in the clinical trial stage. This metric captures the percentage change in net income per share over the last twelve months relative to the previous year. This indicator reflects the business's ability to withstand inflationary costs and rising resource prices. Ignoring macroeconomics turns the search for growth assets into a dangerous illusion. By analyzing the YoY ttm earnings per share trend, an investor can see the real efficiency of capital management.